This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Apollo Endosurgery Management

Management criteria checks 3/4

Key information

Chas McKhann

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage	19.8%
CEO tenure	2.1yrs
CEO ownership	0.4%
Management average tenure	4.3yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chas McKhann's remuneration changed compared to Apollo Endosurgery's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	US$3m	US$550k	-US$40m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$9m	US$375k	-US$25m

Compensation vs Market: Chas's total compensation ($USD2.78M) is above average for companies of similar size in the German market ($USD886.27K).

Compensation vs Earnings: Chas's compensation has been consistent with company performance over the past year.

CEO

Chas McKhann (53 yo)

2.1yrs

Tenure

US$2,780,544

Compensation

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.1m
Jeffrey Black	CFO, Secretary & Treasurer	1.7yrs	US$1.34m	0.18% $ 951.6k
John Molesphini	Executive Vice President of Operations	5yrs	US$662.23k	0.079% $ 422.7k
Sergey Kantsevoy	Co-Founder and Innovation Partner	no data	no data	no data
Anthony Kalloo	Co-Founder and Innovation Partner	no data	no data	no data
Robert Hawes	Co-Founder and Innovation Partner	no data	no data	no data
Peter Cotton	Co-Founder and Innovation Partner	18.3yrs	no data	no data
Christopher Gostout	Co-Founder & Chief Medical Officer	no data	US$1.16m	0.062% $ 331.3k
Sydney Chung	Co-Founder and Innovation Partner	no data	no data	no data
Pankaj Pasricha	Co-Founder	18.3yrs	no data	no data
John Gillings	Investor Relations Manager	no data	no data	no data
Brian Szymczak	Vice President of Legal & Compliance	3.6yrs	no data	no data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: HQ8F's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.1m
John Barr	Independent Chairman of the Board	4.1yrs	US$193.24k	0.051% $ 273.8k
Julie Shimer	Independent Director	4.9yrs	US$164.49k	0.038% $ 199.9k
Richard McGaughy	Independent Director	11.3yrs	US$165.15k	no data
William McClellan	Independent Director	8.9yrs	US$169.49k	0.047% $ 247.9k
Adrian Park	Member of Scientific Advisory Board	no data	no data	no data
Mark Talamini	Member of Scientific Advisory Board	no data	no data	no data
Santiago Horgan	Member of Scientific Advisory Board	no data	no data	no data
Jay Redan	Member of Scientific Advisory Board	no data	no data	no data
Steve McCarus	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Marks	Member of Scientific Advisory Board	no data	no data	no data
David Pacitti	Independent Director	5.4yrs	US$159.70k	0.0067% $ 35.7k

5.2yrs

Average Tenure

58.5yo

Average Age

Experienced Board: HQ8F's board of directors are considered experienced (5.2 years average tenure).

This company listing is no longer active

Apollo Endosurgery Management

Management criteria checks 3/4

Key information

Recent management updates

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Apollo Endosurgery, Inc. Announces Board Changes

CEO, President & Director recently sold €432k worth of stock

Recent updates

Full year 2022 earnings released: US$0.98 loss per share (vs US$0.82 loss in FY 2021)

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.23 loss in 3Q 2021)

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.11 loss in 2Q 2021)

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.17 loss in 1Q 2021)

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Apollo Endosurgery, Inc. Announces Board Changes

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold €432k worth of stock

Chief Financial Officer recently bought €186k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Insider recently sold €105k worth of stock

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

New 90-day high: €6.05

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Revenue beats expectations

Insider recently bought €70k worth of stock

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought €121k worth of stock

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: €3.76

New 90-day high: €2.00

Revenue beats expectations

Third quarter 2020 earnings released: US$0.11 loss per share

New 90-day high: €1.51

New 90-day low - €1.13

New 90-day low - €1.20

First half earnings released

Apollo Endosurgery, Inc. announced that it expects to receive $25 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age